[Therapy of arrhythmia during pregnancy].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001711:Biotransformation; D003374:Coumarins / Q000009:adverse effects; D004077:Digoxin / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D005317:Fetal Growth Retardation / Q000139:chemically induced; D005333:Fetus; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008895:Milk, Human / Q000032:analysis; D010138:Pacemaker, Artificial; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D003374:Coumarins; D004077:Digoxin; D006493:Heparin; D014700:Verapamil; D011802:Quinidine; D011342:Procainamide
Therapie von Herzrhythmusstörungen in der Gravidität.